Author: Ouyang, Lichen; Gong, Jie
Title: Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19 Cord-id: vu7cmwyt Document date: 2020_8_5
ID: vu7cmwyt
Snippet: Immune dysregulation characterized by T cell exhaustion and high level of inflammatory cytokines is associated with severe COVID-19. Figuring out the early event of immune dysregulation would provide a potential treatment for COVID-19. Recent evidence indicate that mitochondrial dysfunction participates in the development of COVID-19 and may be responsible for the dysregulated immune response. Mitochondrial-targeted ubiquinone (MitoQ), a mitochondrial-targeted antioxidant, shows beneficial effec
Document: Immune dysregulation characterized by T cell exhaustion and high level of inflammatory cytokines is associated with severe COVID-19. Figuring out the early event of immune dysregulation would provide a potential treatment for COVID-19. Recent evidence indicate that mitochondrial dysfunction participates in the development of COVID-19 and may be responsible for the dysregulated immune response. Mitochondrial-targeted ubiquinone (MitoQ), a mitochondrial-targeted antioxidant, shows beneficial effects on various diseases through improving mitochondrial dysfunction. We hypothesize that MitoQ could act as a potential treatment in COVID-19. MitoQ may alleviate cytokine storm and restore the function of exhausted T cells in COVID-19 patients through improving mitochondrial dysfunction. In this article, we provide evidence to support the use of MitoQ as a potential treatment or adjunct therapy in the context of COVID-19.
Search related documents:
Co phrase search for related documents- acute lung injury and adaptive immunity innate: 1, 2, 3, 4
- acute lung injury and adjunct therapy: 1
- acute lung injury and liver protection: 1
- acute lung injury and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute lung injury and lymphocyte count: 1, 2, 3
- adaptive immunity and low grade inflammation: 1, 2, 3, 4, 5, 6, 7
- adaptive immunity and lung disease: 1, 2, 3, 4, 5, 6, 7, 8
- adaptive immunity and lung injury: 1, 2, 3, 4, 5, 6, 7
- adaptive immunity and lymphocyte count: 1, 2, 3, 4, 5
- adaptive immunity innate and low grade inflammation: 1, 2, 3, 4, 5, 6
- adaptive immunity innate and lung disease: 1, 2, 3, 4, 5, 6, 7, 8
- adaptive immunity innate and lung injury: 1, 2, 3, 4, 5
- adaptive immunity innate and lymphocyte count: 1
- adjunct therapy and lung disease: 1, 2, 3, 4
- adjunct therapy and lung injury: 1, 2, 3, 4
- adjunct therapy treatment and lung disease: 1
- liver protection and lung injury: 1
- liver protection and lymphocyte count: 1, 2
Co phrase search for related documents, hyperlinks ordered by date